2019
DOI: 10.1158/1538-7445.sabcs18-p4-01-21
|View full text |Cite
|
Sign up to set email alerts
|

Abstract P4-01-21: Multiplexed targeted digital sequencing of circulating tumor DNA to detect minimal residual disease in early and locally advanced breast cancer

Abstract: Background: Circulating tumor DNA (ctDNA) analysis holds potential for minimal residual disease (MRD) detection in early stage breast cancer. However, sensitivity for MRD is limited due to low ctDNA levels in early stage patients and limited blood volumes. Loss of input DNA during library preparation, limited multiplexing or low sensitivity of current molecular methods further limit accuracy. To address this gap, we have developed TARgeted DIgital Sequencing (TARDIS), a novel method for simultan… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“… 11 - 14 To this end, we have developed a novel bespoke platform (targeted digital sequencing [TARDIS]) that ascertains up to 100 baseline mutations in patient FFPE tumor tissue to create a personalized assay for blood sample analysis. 15 Preliminary results from 33 patients with early and locally advanced breast cancer identified pretreatment ctDNA in 100% of patients at a mean concentration of 0.11%. After neoadjuvant chemotherapy, ctDNA dropped to 0.017% and 0.003% in patients with residual disease versus pathologic CR, respectively.…”
Section: Introductionmentioning
confidence: 99%
“… 11 - 14 To this end, we have developed a novel bespoke platform (targeted digital sequencing [TARDIS]) that ascertains up to 100 baseline mutations in patient FFPE tumor tissue to create a personalized assay for blood sample analysis. 15 Preliminary results from 33 patients with early and locally advanced breast cancer identified pretreatment ctDNA in 100% of patients at a mean concentration of 0.11%. After neoadjuvant chemotherapy, ctDNA dropped to 0.017% and 0.003% in patients with residual disease versus pathologic CR, respectively.…”
Section: Introductionmentioning
confidence: 99%